These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29379308)

  • 1. Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma.
    Badawi AM; Osman MA
    Clin Cosmet Investig Dermatol; 2018; 11():13-20. PubMed ID: 29379308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Split-Face Comparison of the Combined Er-YAG Laser and Hydroquinone 4% With Hydroquinone 4% Alone in the Treatment of Melasma in Iranian Patients: A Prospective, Interventional Case Study.
    Namazi N; Hesami A; Ketabi Y
    J Lasers Med Sci; 2020; 11(1):70-73. PubMed ID: 32099630
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the of the efficacy of Fractional Erbium-Doped Yttrium Aluminum Garnet Laser-Assisted Drug Delivery of Kojic Acid in the Treatment of Melasma; A split face, comparative clinical study.
    Al-Dhalimi MA; Yasser RH
    J Cosmet Laser Ther; 2021 May; 23(3-4):65-71. PubMed ID: 34407729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
    Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
    J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial.
    Liang S; Shang S; Zhang W; Tan A; Zhou B; Mei X; Li L
    Front Med (Lausanne); 2023; 10():1132823. PubMed ID: 37056729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A split-face comparison of fractional erbium: YAG laser plus Kligman's formula vs. Kligman's formula monotherapy for facial melasma.
    Nasimi M; Ghiasi M; Lajevardi V; Nasiri F; Shakoei S
    Arch Dermatol Res; 2022 Oct; 314(8):791-797. PubMed ID: 34705101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
    Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
    Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
    Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
    Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma.
    Abdel-Raouf Mohamed H; Ali Nasif G; Saad Abdel-Azim E; Abd El-Fatah Ahmed M
    J Cosmet Dermatol; 2019 Apr; 18(2):517-523. PubMed ID: 30146730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma.
    Pazyar N; Yaghoobi R; Zeynalie M; Vala S
    Clin Cosmet Investig Dermatol; 2019; 12():115-122. PubMed ID: 30858717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study.
    Tehranchinia Z; Saghi B; Rahimi H
    Dermatol Res Pract; 2018; 2018():8350317. PubMed ID: 30079087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Plasma Rich in Growth Factors With Topical 4% Hydroquinone Compared With Topical 4% Hydroquinone Alone in the Treatment of Dermal Type of Melasma: A Single-Blinded Randomized Split-Face Study.
    Amiri R; Karimi Maskooni M; Farsinejad A; Karvar M; Khalili M; Aflatoonian M
    Indian Dermatol Online J; 2024; 15(4):593-598. PubMed ID: 39050052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
    Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
    Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of combined fractional CO
    Tawfic SO; Abdel Halim DM; Albarbary A; Abdelhady M
    Lasers Surg Med; 2019 Jan; 51(1):27-33. PubMed ID: 30431171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractional Erbium-Doped Yttrium Aluminum Garnet Laser Versus Microneedling in Treatment of Atrophic Acne Scars: A Randomized Split-Face Clinical Study.
    Osman MA; Shokeir HA; Fawzy MM
    Dermatol Surg; 2017 Jan; 43 Suppl 1():S47-S56. PubMed ID: 28009690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fractional erbium:YAG laser-assisted tranexamic acid delivery alone and in combination with oral tranexamic acid in melasma.
    Botsali A; Esme P; Erbil H; Caliskan E
    Lasers Med Sci; 2022 Sep; 37(7):2823-2830. PubMed ID: 35347552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Q-Switched Nd:YAG and Fractional Erbium:YAG Lasers in Treatment of Melasma: A Randomized Controlled Clinical Trial.
    Alavi S; Abolhasani E; Asadi S; Nilforoushzadeh M
    J Lasers Med Sci; 2017; 8(1):1-6. PubMed ID: 28912936
    [No Abstract]   [Full Text] [Related]  

  • 18. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
    Lueangarun S; Namboonlue C; Tempark T
    J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
    Mendoza CG; Singzon IA; Handog EB
    Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: A single center, prospective, split-face trial.
    Park SJ; Park JW; Seo SJ; Park KY
    Dermatol Ther; 2022 Mar; 35(3):e15287. PubMed ID: 34962047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.